Telitacicept

Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS) /APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease[1]. The component ratio of this product is Active ingredient : Excipients = 1: 0.5-1: 0.8.

Product Specifications

CAS Number

[2136630-26-5]

Product Name Alternative

RC18

UNSPSC

12352203

Target

TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/telitacicept.html

Purity

99.30

Solubility

10 mM in DMSO

Smiles

[Telitacicept]

Molecular Weight

(75.36 kDa)

References & Citations

[1]Yao X, et, al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci. 2021 Apr 1;159:105704. |[2]Yuxi Yan, et al. Experimental Autoimmune Encephalomyelitis Animal Models Induced by Different Myelin Antigens Exhibit Differential Pharmacologic Responses to Anti-Inflammatory Drugs. Journal of Immunological Sciences. March 31, 2022.